Bod Australia Limited (ASX: BDA) is into the development, manufacturing, and distribution of personal care products. The Company offers skin, beauty, and health care products to spa industries, department stores, pharmacies, and home shopping networks. Bod Australia markets its products globally.
The company has its extensive distribution through pharmacy, speciality health food stores, online and retail – including established relationships with Australia’s largest pharmacy groups. The company is Delivering innovation through deliverable methods, plant-based extraction and market positioning. The company is pretty well positioned, to target the USD 1 Trillion Global Health and Wellness Markets.
The company has recently published it's Asia and Australian Roadshow Presentation. In the presentation, the company has showcased its Record revenue of $1.22m achieved (product sales: $766,000) for the three months ending 31 December 2018 which is 260 percent higher than Q1 FY 2019. The company’s Increased sales from agreements with Priceline Pharmacies with further product uptake from independents. The Base run rate grew 248% during Q2 FY 2019 which is providing a robust platform for coming quarters and beyond. The company is expanding its product offering across all brands.
The firm has Recently raised $6.4 million to drive growth and global expansion. Executive and Non- Executive Directors all participated in the recent capital raise. Medicabilis™ medicinal cannabis oil now being prescribed through Australia’s patient special access scheme (SAS-B).
On the Research & development front, the Formulations for nutraceutical range utilising CBD extract
is being developed for Europe and the UK. The company has started its European expansion and it is having plans to capitalise on the three largest cannabis markets in Europe with executive staff now in place. The export licence has been granted & additional licences are expected to come to the firm in due course. The company is slated to be a fast mover in the in the medicinal cannabis markets, underpinned by two global partnerships, the one being a Supply and collaboration agreement with Linnea Natural Pharma Solution & the other with iXBiopharma to use its WaferiXTM delivery technology. The company also hold import and Export licences for Medicinal Cannabis in Australia.
Now let us quickly have a look at the company’s stock performance and the return it has posted over the last few months. The stock is currently trading at a price of $0.470 and is trading up by 2.174% during the day’s trade, with a market capitalisation of $31.92 million. The counter opened the day at $0.475, reached a day’s high of $0.49 & touched a day’s low of $0.470. The stock has yielded a Year till Date returns of 17.95% and posted returns of -8.91%, -19.30% & -13.58% over the past six months, three months & one-month period respectively. It had a 52-week high price of $0.715 and touched 52 weeks low of $0.330, with an average volume of 152,002 approximately.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.